Can-C N-acetylcarnosine Eyedrops for Senile Cataracts Now Patent Approved

Share Article

International Antiaging Systems (IAS) are pleased to announce that Can-C cataract eye drops have been recognised by the US patent office and that its patent came into force at the end of 2010.

International Antiaging Systems (IAS) are pleased to announce that Can-C cataract eye drops have been recognised by the US patent office and that its patent came into force at the end of 2010.

Dr. Mark Babizhayev its inventor at Innovative Vision Products commented; “it is great news that Can-C has been granted its patent license in the USA after many years of patent pending. It is recognition of all our work in studying, testing and proving that Can-C is efficacious and of great value to the aging community.”

IAS Vice President Phil Micans said “it’s hard for me to believe that we launched Can-C in 2003 more than 8 years ago; whilst we know it has helped many thousands of people and even dogs! We also appreciate that the vast majority of the public are still unaware that they can prevent, delay and even reverse their cataract with an eye-drop!”

Can-C is an important discovery because, for the first time ever, it offers an effective alternative to cataract extraction surgery. This is because Can-C not only protects the eye tissues from harmful free radicals, it also reverses existing damage. Can-C eye-drops allow the patient to keep their natural lens rather than cope with an artificial one.

With age, our body produces more harmful free radicals and less natural antioxidants to defend against them. It’s this excessive free radical damage – known as oxidation – and its sister process known as glycosylation- which can cause chronic tissue damage and lead to cataracts. But Can-C contains a natural di-peptide known as N-acetylcarnosine which delivers L-carnosine into the aqueous humor of the eye (the fluid area surrounding the lens) where it acts as a natural and comprehensive anti-oxidant, protecting structural lens proteins from the free-radical induced oxidation process.

The statistics from the human trials show that Can-C eye-drops applied for 6-months twice daily into the eye in patients suffering from senile cataract had the following results: 88.9% had an improvement of glare sensitivity, 41.5% had an improvement of the transmissivity of the lens and 90% had an improvement in visual acuity.

International Antiaging Systems (IAS) has dedicated itself to supplying the very latest commercially available products, giving you direct access to many different types of “hard to obtain” substances. At the same time they demand that everything they offer meets the highest possible pharmaceutical standards. For further reading sections please visit: http://www.antiaging-systems.com

###

Share article on social media or email:

View article via:

Pdf Print